- Home
- OGC vs PRAX Comparison
OGC vs PRAX Comparison
Compare OGC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGC | PRAX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.1B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OGC | PRAX |
|---|---|---|
| Price | $24.86 | $309.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $572.13 |
| AVG Volume (30 Days) | 293.1K | ★ 332.8K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,758.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.90 | $37.25 |
| 52 Week High | $26.88 | $366.52 |
Technical Indicators
Market Signals| Indicator | OGC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 41.68 |
| Support Level | $23.76 | $284.87 |
| Resistance Level | $25.41 | $343.96 |
| Average True Range (ATR) | 0.94 | 18.42 |
| MACD | 0.14 | -3.20 |
| Stochastic Oscillator | 69.23 | 5.61 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.